Effect of KRAS Exon 2 Mutations on Antitumor Activity of Afatinib and Gefitinib

Anti-Cancer Drugs - United States
doi 10.1097/cad.0000000000000196
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

PLoS Medicine
BiochemistryBiotechnologyMolecular BiologyCell BiologyMedicine
2005English

Antitumor Effect of Gefitinib on Head and Neck Squamous Cell Carcinoma Enhanced by Trastuzumab

Oncology Reports
MedicineCancer ResearchOncology
1994English

Synergistic Effect of Afatinib With Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib

PLoS ONE
Multidisciplinary
2013English

Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination With PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2014English

Effect of the Metal Center on the Antitumor Activity of the Analogous Dinuclear Spermine Chelates (PdCl2)2(Spermine) and (PtCl2)2(Spermine)

Letters in Drug Design and Discovery
Drug DiscoveryMolecular MedicinePharmaceutical Science
2007English

PC04.01 Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First Versus Osimertinib First)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Antitumor Activity of Sorafenib Plus CDK4/6 Inhibitor in Pancreatic Patient Derived Cell With KRAS Mutation

Journal of Cancer
Oncology
2018English

Antitumor Activity of 2, 6-Bis (Halomethyl) Piperidines on Ehrlich Ascites Carcinoma

Yakugaku Zasshi
PharmacologyPharmaceutical Science
1977English

Allelic Ratio of KRAS Mutations in Pancreatic Cancer

Oncologist
Cancer ResearchMedicineOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy